Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
In past decades, anticancer research has led to remarkable results despite many of the approved drugs still being characterized by high systemic toxicity mainly due to the lack of tumor selectivity and present pharmacokinetic drawbacks, including low water solubility, that negatively affect the drug circulation time and bioavailability. The stability studies, performed in mild conditions during their development or under stressing exposure to high temperature, hydrolytic medium or light source, have demonstrated the sensitivity of anticancer drugs to many parameters. For this reason, the formation of degradation products is assessed both in pharmaceutical formulations and in the environment as hospital waste. To date, numerous formulations have been developed for achieving tissue-specific drug targeting and reducing toxic side effects, as well as for improving drug stability. The development of prodrugs represents a promising strategy in targeted cancer therapy for improving the selectivity, efficacy and stability of active compounds. Recent studies show that the incorporation of anticancer drugs into vesicular systems, such as polymeric micelles or cyclodextrins, or the use of nanocarriers containing chemotherapeutics that conjugate to monoclonal antibodies can improve solubility, pharmacokinetics, cellular absorption and stability. In this study, we summarize the latest advances in knowledge regarding the development of effective highly stable anticancer drugs formulated as stable prodrugs or entrapped in nanosystems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403 · cited 2×
“Growth inhibitor Axitinib Renal-cell carcinoma [57] Bortezomib Multiple myeloma [58]”
BackgroundGarcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102017 · Cited by 1,159 · cited 1×
“Monoclonal antibody Bevacizumab Metastatic colorectal cancer, metastatic breast cancer, non-small-cell lung cancer, glioblastoma, renal-cell carcinoma, ovarian cancer and cervical cancer [53]”
Backgroundde Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421 · cited 1×
“Campotothecins SN-38 (7-ethyl-10-hydroxycamptothecin) Irinotecan Solid tumors, including colorectal, pancreatic and lung cancer [48]”
BackgroundSupramolecular cancer nanotheranostics
Zhou, J., Rao, L., Yu, G., Cook, T. R., Chen, X., & Huang, F. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00011f · Cited by 411 · cited 1×
“Most of the reviews published in the literature focus on the drawbacks of anticancer drugs [82,83] or the use of nanocarriers as DDS [84,85].”
BackgroundThe safety of bortezomib for the treatment of multiple myeloma
Cengiz Seval, G., & Beksac, M. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1513487 · Cited by 117
Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin
Zou, L., Ding, W., Zhang, Y., Cheng, S., Li, F., Ruan, R., Wei, P., & Qiu, B. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.08.013 · Cited by 92
Qiu, C., & Arzhantsev, S. (2018) · Analytical Biochemistry · doi:10.1016/j.ab.2018.06.003 · Cited by 11
Cited by
PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy
Kesharwani, P., Kumar, V., Goh, K. W., Gupta, G., Alsayari, A., Wahab, S., & Sahebkar, A. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02410-x · Cited by 132
“Several anticancer drugs have low water solubility and chemical instability, which may impact body absorption capacity and cancer therapy efficiency [5, 34–41].”
Sarkar, R., Biswas, S., Ghosh, R., Samanta, P., Pakhira, S., Mondal, M., Dutta Gupta, Y., Bhandary, S., Saha, P., Bhowmik, A., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02518-0 · Cited by 69
Exosome-based drug delivery systems for enhanced neurological therapeutics
Vahab, S. A., V, V. K., & Kumar, V. S. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01710-x · Cited by 34
Metadata
- Authors
- Ioele, G., Chieffallo, M., Occhiuzzi, M. A., De Luca, M., Garofalo, A., Ragno, G., & Grande, F.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-08-25
- Volume
- 27
- Issue
- 17
- Pages
- 5436
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W4293217939
- Cited by
- 222
- References
- 7
- FWCI
- 9.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties. https://app.cochat.ai/papers/10.3390/molecules27175436
- The paper
- Ioele, G., Chieffallo, M., Occhiuzzi, M. A., De Luca, M., Garofalo, A., Ragno, G., & Grande, F. (2022). Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties. Molecules. https://doi.org/10.3390/molecules27175436
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.